On this week’s Tech Nation, with the 44th Annual J.P. Morgan Healthcare Conference around the corner, we delve into three ongoing efforts in biotech. Moira speaks with Cyriac Roeding and Dr David Suhy, Co-Founders of Earli, about their innovative approach to treating solid tumour cancer. Then, Ketan Mehta of Tris Pharma discusses the potential of a euphoria-suppressing opioid. And Neil Klompas of Augurex Life Sciences talks about a new diagnostic for patients with chronic back pain that pinpoints an easily-missed form of arthritis.

BTN TITLE: Can Cancer Cells be Turned Against Themselves?

This week on BioTech Nation, Moira speaks with Cyriac Roeding and Dr David Suhy, Co-Founders of Earli, about an innovative new approach to solid tumour cancer. They discuss their effort to turn the cancer cells inside solid tumours into factories that produce their own cancer-fighting therapies.

On this week’s Tech Nation, Moira speaks with author and environmental thought leader Paul Hawken to discuss his latest book, "Carbon: The Book of Life", about the invisible forces shaping our planet and the actions that can transform our future. He challenges us to rethink climate, commerce, and our own beliefs.

On this week’s Tech Nation, Moira speaks with Dr Christopher Summerfield, Professor of Cognitive Science at the University of Oxford and author of "These Strange New Minds … How AI Learned to Talk and What It Means," on how AI is changing our world. Then, Professor Niels Riedemann, Co-Founder & CEO of InflaRx, explains how the body’s immune system sometimes turns against itself and what can be done to prevent it.

On this week’s Tech Nation, Moira speaks with Dr. Alexandra Shaker, Clinical Psychologist and author of "The Narrowing … A Journey Through Anxiety and the Body," exploring what anxiety really is and how our gut instinct and genetics play a role in our response. Then, Dr. Thomas Chen, Director of Neuro-oncology at USC and Founder of NeOnc Technologies, discusses an innovative method to deliver drugs directly to the brain to treat glioblastoma and other brain cancers.

On this week’s Tech Nation, Emeritus Professor of Economics, Gary Smith, addresses the question of an AI bubble: is there one? And what will be the economic impact if it bursts? Then, CEO Martin Burns explains how Bruin Biometrics aims to prevent a potentially fatal condition affecting more than 2.5 million Americans each year.

BTN Title: Preventing Pressure Injuries: Detecting the Invisible Signs

Bruin Biometrics CEO, Martin Burns, talks about a new diagnostic tool being used to detect and prevent potentially fatal bedsores in their earliest stages.

On this week’s Tech Nation, Moira speaks with Dr. Ashley Shew, Professor of Science, Technology, and Society at Virginia Tech and author of, "Against Technoableism... Rethinking Who Needs Improvement", about how technology influences our perception of disability and whether it truly helps those it aims to support. Then, Dr. Ari Azhir, CEO of Neuvivo, discusses how her company revived a once-failed ALS drug by re-examining clinical trial data, uncovering its potential to treat Huntington’s, Alzheimer’s, and Vascular Dementia.

On this week’s Tech Nation, Moira speaks with Sonia Purnell about her book, “A Woman of No Importance,” and the story of Virginia Hall, an American spy who operated in Nazi-occupied France during World War II, even with her wooden leg. Then, Dr. Lincoln Nadauld, President & CEO of Culmination Bio, discusses how medical records and biological data are being combined with technology to answer unprecedented questions in medicine.

On this week’s Tech Nation, Moira speaks with

Terry Healey about "The Resilience Mindset … How Adversity Can Strengthen Individuals, Teams, and Leaders". Then Lisa Dechamps tell us how Aviado Bio is working to correct the gene driving many cases of frontotemporal dementia. And Columbia University professor Dr. Sandra Matz describes the science of psychological targeting”.

BTN Title: Correcting Gene-based Frontotemporal Dementia

Lisa Dechamps tell us how Aviado Bio is working to correct the gene driving many cases of frontotemporal dementia.